Cancer Vaccines Market Overview:
Global Cancer Vaccines Market was valued at $4,073 million in 2016, and is expected to reach at $12,814 million by 2023, registering a CAGR of 17.7% from 2017 to 2023.
Vaccine is a biological preparation administered to produce acquired immunity in patients as well as healthy individuals. Cancer vaccines are a type of biological therapy that prevents and heals various types of cancer such as, cervical cancer, prostate cancer, lung cancer, breast cancer, and others. These vaccines are designed specifically to recognize and reduce the growth of cancer cells by the immune system. Moreover, cancer vaccines are expected to reduce the prevalence and incidence rate of cancer.
The global cancer vaccines market is driven by increase in the prevalence of human papilloma virus (HPV) infections, rise in administration of prophylactic cancer vaccines, surge in investments & government funding in the development of cancer vaccines, and launch of new cancer vaccines in the market. However, high cost for developing cancer vaccines due to the need for frequently upgradating in manufacturing technology and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth. Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines are expected to offer lucrative opportunities in the near future.
Global Cancer Vaccines Market Segmentation
The global cancer vaccines market is segmented based on technology, type, indication, end use, and region. Based on technology, it is classified into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. Based on indication, it is divided into cervical cancer, prostate cancer, and others. Based on end use, it is categorized into pediatric and adult vaccines. Region wise itis analyzed across four North America, Europe, Asia-Pacific, and LAMEA.
India Cancer Vaccines Market
The pediatric cancer vaccines segment possesses high market potential for growth in the market, owing to increasing traction of prophylactic vaccines among children. However, the adult cancer vaccines segment dominated the global market throughout the forecast period, owing to increase in incidence of human papilloma virus infections in adults. Furthermore, increase in cancer incidence in India causing approximately 6,00,000‐7,00,000 deaths in 2012, increases the need for prophylactic and therapeutic cancer vaccines.
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new markets and increase in transition from prophylactic to therapeutic cancer vaccines is expected to provide new growth opportunities in the near future.
Drivers, Restraints, and Opportunities
The key players profiled in the report are Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.
The other key players in the value chain include Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.
- The study provides an in-depth analysis, current trends, and future estimations of the global cancer vaccines market to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- A quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of key segments of the industry is provided to understand the type of products and indications used globally.
- Key market players and their strategies are analyzed to understand the competitive outlook of the market.
Cancer Vaccines Market Key Segments:
- Dendritic Cells (DC) Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Whole Cell Cancer Vaccines
- Viral Vector & DNA Cancer Vaccines
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Cervical Cancer
- Prostate Cancer
By End Use
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Rest of LAMEA